bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2017: O S A J J M A M F J
2016: D N O

 
  Other news for:
Headache
Child
Migraine
Placebos
 Resources from HONselect
Study Questions Use of Migraine Meds in Kids, Teens
Researchers found sugar pill worked as well as commonly prescribed drugs

By Robert Preidt

THURSDAY, Oct. 27, 2016 (HealthDay News) -- A new study raises questions about the effectiveness of medicines commonly prescribed to prevent migraines in children and teens.

The 24-week clinical trial involving 328 patients found no significant differences between the drugs amitriptyline (Elavil), topiramate (Topamax) and a placebo sugar pill in reducing the number of days with a migraine or migraine-related disability.

Fifty-two percent of those taking amitriptyline and 55 percent of those taking topiramate saw the number of days they had a headache drop by 50 percent or more, while 61 percent of those taking a placebo pill saw the same benefit, the findings showed.

The patients taking the prescription drugs also had much higher rates of side effects, such as fatigue, dry mouth, mood changes, and tingling in the hands, arms, legs or feet.

"The study was intended to demonstrate which of the commonly used preventive medications in migraine was the most effective. What we found is that we could prevent these headaches with either a medication or a placebo," said senior study author Dr. Andrew Hershey. He is co-director of the Headache Center at Cincinnati Children's Hospital Medical Center.

"This study suggests that a multidisciplinary approach and the expectation of response is the most important, not necessarily the prescription provided," he added in a hospital news release.

The researchers were "hoping to develop evidence to drive the choice by medical providers of the first-line prevention medication for helping youth with migraine, but the data showed otherwise," said study first author Scott Powers. He is a pediatric psychologist and co-director of the Headache Center.

"We see this as an important opportunity for health care providers, scientists, children and families, because our findings suggest a paradigm shift," Powers said.

"First-line prevention treatment will involve a multidisciplinary team approach and focus on non-pharmacological aspects of care. The good news is we can help children with migraines get better," Powers said.

The findings were published Oct. 27 in the New England Journal of Medicine.

More information

The Migraine Research Foundation has more about migraine in children and teens.

SOURCE: Cincinnati Children's Hospital Medical Center, news release, Oct. 27, 2016

Copyright © 2016 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=716223

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Headache
Specialty Chemicals and Products
Research Personnel
Health Personnel
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact